Nicotinamide Riboside + Exercise 6-Week Pilot Trial in Older Adults with Hypertension

A randomized double-blind pilot trial evaluating nicotinamide riboside (NR) supplementation combined with exercise was published in GeroScience. 54 sedentary adults aged 55+ received NR 1,000 mg/day plus 3x weekly 30-min walking for 6 weeks. Combined with the same period’s NICE trial showing NR’s effects in peripheral artery disease, the clinical adaptation domain for NAD+ boosters is refining.

Trial design

Participants: Sedentary adults 55+ with mildly elevated systolic blood pressure (120-139 mmHg). 54 patients.

Randomization: NR 1,000 mg/day + exercise / placebo + exercise / NR alone.

Duration: 6 weeks.

Primary endpoint: Systolic blood pressure and arterial stiffness changes.

The trial’s distinguishing design is measuring NR-exercise synergy. Effects of exercise alone, NR alone, and the combination are assessed separately.

Core results

Major signals from published data.

Systolic blood pressure reduction: Meaningful reduction in NR + exercise combination arm. Possibly larger change than monotherapy of exercise or NR.

Arterial stiffness improvement: Meaningful improvement on some measures.

NAD+ level recovery: NR arm showed meaningful blood NAD+ level increase. Mechanism validation.

Side effects: Generally mild. GI discomfort most common.

The significance: NR may sit as a synergy drug that boosts exercise effects. Some effects alone, stronger effects combined with exercise.

Additional NICE trial data

The simultaneously published NICE trial (NR in peripheral artery disease) provides another dimension.

Participants: Peripheral artery disease (PAD) patients.

Intervention: NR supplementation.

Core result: Meaningful improvement in 6-minute walk distance (6MWD). An objective measure of exercise capacity.

Mechanism clue: Skeletal muscle mitochondrial function recovery.

PAD is leg artery atherosclerosis causing pain and walking distance limits. NR improving 6MWD signals composite recovery of skeletal muscle oxygen utilization, mitochondrial function, and vascular endothelial function.

Mechanism

NR is a vitamin B3 family molecule and an efficient precursor of the NAD+ biosynthesis pathway. As NAD+ declines with age, these systems are affected.

Sirtuins (SIRT1-SIRT7): NAD+-dependent protein deacetylases. Regulate mitochondrial biogenesis, DNA repair, autophagy.

PARP: NAD+-dependent DNA repair enzymes.

CD38: NAD+-degrading enzyme (activity rises with age).

When NR restores NAD+, SIRT1, PARP, and others reactivate. This is the molecular clue for mitochondrial function, vascular endothelial function, and skeletal muscle efficiency recovery.

NR vs NMN

Two molecules in the same NAD+ booster category.

NR (Nicotinamide Riboside): Vitamin B3 form. Trace amounts in food (milk, yeast). Most common on market. Rich clinical data. Absorption and safety well-established.

NMN (Nicotinamide Mononucleotide): One step downstream from NR in the NAD+ synthesis pathway. Some hypotheses suggest more direct effect. Less human clinical data than NR. US FDA supplement classification debate.

Both molecules show NAD+ recovery effect. Clinical outcome differences remain undetermined. NR is more securely positioned in the market; NMN is developing.

Synergy with exercise

The most important message from this trial is the synergy with exercise.

Exercise itself is the most powerful natural NAD+ stimulus. Aerobic + resistance training activates SIRT1 and mitochondrial biogenesis. NR supplementation alone cannot replace exercise.

But NR may boost exercise effects. For populations with insufficient response to exercise alone (elderly, PAD, sarcopenia), adding NR is a reasonable matrix option.

Who fits

Middle-aged + older (55+) sedentary: Population with mildly elevated blood pressure who’s starting exercise.

Peripheral artery disease or walking distance limits: After clinician consultation.

Active aging targeting: Mitochondrial function and vascular health targets.

Comparing with NMN populations: Choice between the two.

Who should be careful

Pregnancy/breastfeeding: Insufficient data.

On prescription drugs: Consult a clinician. Some drug interactions.

GI sensitive: Take with meals. Mild GI discomfort possible.

High-dose self-prescribing: 1 g/day+ is clinical-validated. Above that lacks data.

Connection to other matrices

NR is one axis of the aging mechanism matrix.

Mitochondria: NAD+ recovery → SIRT1, PGC-1α → mitochondrial biogenesis. Different path from Lancôme x Timeline’s Urolithin A (mitophagy).

Vascular + arterial stiffness: Different mechanism from vitamin K2 (MK-7) arterial calcification inhibition. The two complement.

Muscle + exercise capacity: Different path from this quarter’s GLP-1 + BELIEVE matrix muscle preservation and K2 TAKEOVER neuromuscular EMD. NR targets skeletal muscle mitochondrial efficiency.

Cognition: NR’s blood-brain barrier crossing potential data. Some cognitive trials in progress.

Skin: Topical niacinamide’s skin effects (wrinkles, pigment, barrier) and the same NAD+ system via different paths. Oral + topical integration possible.

Daily guide

Dose: NR 250-1,000 mg/day. Clinical range.

Timing: With meals or after meals. Empty stomach can cause irritation.

Duration: Assess effect after 4-12 weeks. Continue if effective.

Combinations: Exercise (3x weekly+), vitamin D, vitamin K2 (MK-7), omega-3, sufficient protein. NR isn’t the center but one axis of the matrix.

Diet first: Trace amounts in milk, yeast, some fermented foods. Reaching clinical doses through diet alone is difficult; supplements are efficient.

NR isn’t a cure-all. A targeted supplement added on top of exercise and dietary foundation. Use within the matrix matched to your stage and target.